The Pediarix™ vaccine is a combination DTaP, hepatitis B, and IPV (polio) vaccine manufactured by GlaxoSmithKline. It is a combination of their existing DTaP product (Infanrix), hepatitis B (Engerix-B) vaccine, and an additional polio (IPV) component. The vaccine approved for use in 2003. It was studied both for safety and efficacy (to be sure it induced an adequate immune response when given as a combination vaccine) prior to approval by the FDA. It continues to appear safe and effective. The use of this combination vaccine saves between 3 to 6 injections during the first 2 years of life.
For information on diseases, side effects, etc., see the information on the component vaccines: DTaP, Hepatitis B, IPV. The Pediarix vaccine does not contain thimersol (mercury).
Schedule
The vaccine is given at 2, 4, and 6 months of age.
Related information and resources
References
Notice to Readers: FDA Licensure of Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), and Poliovirus Vaccine Combined, (PEDIARIX™) for Use in Infants MMWR, Mar 14, 2003, Vol 52, #10
